Related Experiment Videos
PI3K/Akt signalling pathway and cancer
Juan Angel Fresno Vara1, Enrique Casado, Javier de Castro
1Cátedra de Oncología y Medicina Paliativa, Servicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana 261, Madrid 28046, Spain.
Cancer Treatment Reviews
|March 17, 2004
Summary
The phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathway regulates cell survival and growth. Aberrant PI3K/Akt signaling contributes to cancer drug resistance by inhibiting apoptosis, highlighting its therapeutic potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Phosphatidylinositol-3 kinases (PI3Ks) generate the second messenger phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3).
- PI3K/Akt signaling pathway components are frequently altered in human cancers.
- Therapeutic resistance in cancer is often linked to impaired apoptosis induction.
Purpose of the Study:
- To elucidate the role of the PI3K/Akt pathway in cancer.
- To understand the contribution of PI3K/Akt signaling to therapeutic resistance.
- To explore the PI3K/Akt pathway as a target for novel cancer therapies.
Main Methods:
- The abstract does not specify methods.
- The abstract focuses on signaling pathway analysis and its implications in cancer.
Main Results:
- PI3K activation leads to the production of PI-3,4,5-P3 and PI(3,4)P2.
- Activated Akt regulates cell survival, cell cycle progression, and growth.
- The PI3K/Akt pathway mediates survival signals, contributing to a resistant phenotype in tumor cells.
Conclusions:
- The PI3K/Akt pathway plays a critical role in cancer cell survival and resistance to therapy.
- Targeting the PI3K/Akt pathway is a promising strategy for overcoming drug resistance in cancer.
- Understanding this pathway is crucial for developing effective cancer treatments.